The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AngioDynamics's revenues will expand 49.9% and EPS will wither -40.0%.
The average estimate for revenue is $86.5 million. On the bottom line, the average EPS estimate is $0.06.
Last quarter, AngioDynamics logged revenue of $81.6 million. GAAP reported sales were 57% higher than the prior-year quarter's $51.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.08. GAAP EPS were -$0.03 for Q3 compared to -$0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 50.3%, 670 basis points worse than the prior-year quarter. Operating margin was 7.1%, 430 basis points better than the prior-year quarter. Net margin was -1.2%, 220 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $338.5 million. The average EPS estimate is $0.33.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 99 members out of 113 rating the stock outperform, and 14 members rating it underperform. Among 35 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give AngioDynamics a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $13.10.
Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AngioDynamics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Cardiac-Care Stocks That Could Bring Heart-Stopping Gains
Investors hit the jackpot with cardiac-care stocks last year. Here are three stocks primed to continue the heart-stopping gains.
A Trio of Stock Prospects in Medical Devices
What is the outlook for AngioDynamics, DexCom, and Abiomed?
Will AngioDynamics Earnings Rise With Its Soaring Stock?
MAKO and Intuitive Surgical's successes have overshadowed this small medical-device maker, but its shares have risen to two-year highs. Will AngioDynamics earnings live up to the company's promise?